S. Korean company to start clinical trial for potential coronavirus treatment in U.S.
By Kim Han-joo
SEOUL, June 11 (Yonhap) -- South Korean biopharmaceutical maker Genexine Inc. said Thursday it has won approval to conduct a clinical trial for its potential coronavirus treatment in the United States.
The U.S. Food and Drug Administration (FDA) gave the green light for the phase 1 clinical trial of anti-cancer drug candidate GX-I7 for treating COVID-19 patients, according to the company.
GX-I7 -- co-developed by U.S.-based biopharmaceutical firm NeoImmuneTech Inc. -- will be administered in adult COVID-19 patients with mild symptoms, the company said.
GX-I7 is the immuno-therapeutic drug that fuses cytokine interleukin-7, which plays an essential role in the proliferation of T cells in the body.
Genexine is currently also part of a six-firm consortium that includes SK Life Science Inc., a unit of the country's No. 3 conglomerate SK Group, in developing novel COVID-19 vaccines.
The Genexine consortium has successfully carried out an experiment of its vaccine candidate on monkeys, with consortium member Binex completing the production of a sample.
khj@yna.co.kr
(END)
-
Pelosi to meet Nat'l Assembly speaker amid heightened regional tensions over Taiwan visit
-
BTS could be allowed to perform overseas during military service: defense minister
-
(LEAD) N. Korea slams Pelosi's Taiwan visit, backs China's position
-
U.S. House Speaker Pelosi arrives in S. Korea amid Sino-U.S. tensions over Taiwan
-
(2nd LD) Kim, Pelosi agree to support efforts for denuclearization of N. Korea
-
(2nd LD) Kim, Pelosi agree to support efforts for denuclearization of N. Korea
-
(LEAD) Assembly speaker meets with Pelosi amid heightened Sino-U.S. tensions
-
BTS could be allowed to perform overseas during military service: defense minister
-
(2nd LD) Yoon calls Pelosi's visit to Seoul sign of deterrence against N. Korea
-
Pelosi to meet Nat'l Assembly speaker amid heightened regional tensions over Taiwan visit
-
N. Korea appears to release border dam water without prior notice: official
-
(2nd LD) Central region suffers damage after heavy rain
-
(LEAD) Central region suffers damage after heavy rain
-
Education minister expected to resign amid criticism of proposal to lower school entry age
-
Whereabouts of 55 Thai tourists on Jeju unknown